stockrowLENZ Therapeutics, Inc.
LENZ Healthcare Biotechnology
LENZ Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $19.1 million.
- Revenue
- −72.9%
- EPS
- −67.1%
- Free cash flow
- −147.2%
Quarter to September 2026, against a year earlier
Follow LENZ
Alert me
LENZ Therapeutics, Inc. (LENZ) Piotroski F-score
LENZ Therapeutics, Inc.'s Piotroski F-score for fiscal 2025 cannot be worked out: no comparable prior fiscal year (a missing year or a changed year end).
Piotroski F-score, annual
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | — | — | n/a | — |
| Positive operating cash flow | (69.17m) | — | Fail | 0 |
| Rising return on assets | — | — | n/a | — |
| Cash flow above net income | 12.96m | — | Pass | 1 |
| Falling long-term leverage | — | — | n/a | — |
| Rising current ratio | 14.23 | — | n/a | — |
| No new shares issued | 28,813,000 | — | n/a | — |
| Rising gross margin | 97.81% | — | n/a | — |
| Rising asset turnover | — | — | n/a | — |
| Piotroski F-score | n/a — no comparable prior fiscal year (a missing year or a changed year end) | — | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| ICCC ImmuCell Corporation compare | 7 |
| VXRT VAXART, INC. compare | 6 |
| VANI Vivani Medical, Inc. compare | 5 |
| BDTX Black Diamond Therapeutics, Inc. compare | — |
| LENZ LENZ Therapeutics, Inc. | — |
| UNCY Unicycive Therapeutics, Inc. compare | — |
| NMRA Neumora Therapeutics, Inc. compare | — |
| PMVP PMV Pharmaceuticals, Inc. compare | — |
| NRXP NRx Pharmaceuticals, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover